Related Experiment Videos
Concurrent administration of interferon alfa-2b and beta-1a
Tawee Tanvetyanon1, Edward A Stadtmauer, Lawrence A Kerson
1Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA. ttanve@lumc.edu
The Annals of Pharmacotherapy
|December 31, 2002
Summary
Concurrent use of interferon (IFN) alfa and beta was well tolerated in a patient with multiple sclerosis and chronic myeloid leukemia. This combined treatment achieved hematologic remission with manageable side effects.
Area of Science:
- Neurology
- Hematology
- Immunology
Background:
- Multiple sclerosis (MS) and chronic myeloid leukemia (CML) are distinct conditions requiring specific treatments.
- Interferon (IFN) beta is a standard therapy for MS.
- IFN alfa is used in CML treatment.
Observation:
- A 60-year-old male with MS developed CML while on IFN beta-1a therapy.
- He was treated concurrently with IFN alfa-2b and IFN beta-1a, with a gradual dose increase of IFN alfa.
- The patient achieved complete hematologic remission within 3 months.
Findings:
- The combined IFN alfa and beta therapy was well tolerated.
- Adverse effects were mild, including fatigue, somnolence, weight loss, and memory difficulties.
- The patient maintained hematologic remission and stable MS status for 19 months.
Implications:
- Concurrent use of IFN alfa and beta can be a safe treatment option for patients with both MS and CML.
- This approach may benefit patients for whom imatinib mesylate is not suitable.
- Further research into combined interferon therapy for comorbid conditions is warranted.